This review concluded that treatment with local tetracycline and 0.12% chlorhexidine mouth rinse have significant and clinically relevant effects on the prevention of alveolar osteitis following the surgical removal of lower third molars.  Overall, the data support the authors’ conclusions, but the poor quality of many of the studies may limit its reliability.

To evaluate randomised controlled trials (RCTs) for the prevention of alveolar osteitis (AO) following tooth extraction.

MEDLINE and the Cochrane Library were searched from October 2004 to October 2005; the search terms were reported.  The reference lists of retrieved publications were screened for additional studies.  Only studies written in English, French, German or any of the Nordic languages (Danish, Finnish, Icelandic, Norwegian, Swedish) were eligible for inclusion in the review.

RCTs were eligible for inclusion in the review.  Trials with flawed analyses (e.g. using patients as the unit of randomisation, but teeth as the unit of analysis) were excluded from the review.

Studies of interventions to prevent AO were eligible for inclusion. The included trials assessed antibiotics (tetracycline, amoxicillin, clindamycin and metronidazole), 0.12% chlorhexidine mouth rinse, propylic ester of para-hydrobenzoic acid (PEPH), and other interventions (e.g. saline rinses, local anaesthetics, gloves, coronectomy, iodine washes).  Trials assessing other interventions usually compared different interventions, whilst trials of antibiotics, chlorhexidine and PEPH usually compared interventions with placebo or in some cases no treatment. 

Studies of patients undergoing tooth extractions were eligible for inclusion.  The majority of the included studies and the review’s conclusions focused on the surgical removal of lower third molars. Nearly half of the studies originated from Nordic countries; 31% originated from North America, with the remainder from the UK, New Zealand, Italy, Turkey, Nigeria and China.

The frequency of AO was assessed.  The included studies followed up patients from 4 days to 3 weeks.  AO was defined in 75% of the studies and 16% used the definition of Birn. Studies which primarily assessed post-operative complications were excluded from the review.

The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.

Two authors rated the quality of each study twice using the Jadad scale.  An overall total of up to 5 points were awarded according to the method of random allocation, double-blinding, and the reporting of withdrawals and drop-outs.  Studies scoring 0 to 2 points were poor quality and those scoring 3 to 5 points were high quality.  In addition the reporting of a definition of AO and an a priori power calculation were also assessed.

Two reviewers independently extracted the data and any disagreements were resolved through consensus.  Absolute risk reductions (ARR) and numbers-needed-to-treat (NNT) were calculated, along with 95% confidence intervals (CIs).  Data from spit-mouth trials were considered paired data.

The authors reported that differences in study design and the reporting of study methods precluded meta-analysis; therefore the studies were combined in a narrative.

Some differences between the studies were evident from the data tables and were discussed in the text.

Thirty-two RCTs (n=8,462) were included in the review.

The mean Jadad score was 2.7 points (range: 1 to 5); half of the studies were considered poor quality.  Half of the studies failed to report the method of randomisation used, while an appropriate method of double-blinding was only reported in 47%.  The reporting of withdrawals and drop-outs was only complete in 22% of the studies. Only 13% of studies reported a priori power calculations.

Antibiotic trials (8 RCTs).
The ARR ranged from 0.8 to 31 % and the NNT from 3 to 125 treated individuals.  All 3 tetracycline trials (two poor quality and one high quality) showed statistically significant effects in favour of the treatment group compared with the control (the ARR ranged from 12 to 31% and the NNT from 3.2 to 8.3).  However, of the remaining trials of amoxicillin (1 RCT), clindamycin (1 RCT) and metronidazole (3 RCTs), only the RCT of clindamycin showed a significant effect in favour of the intervention group.

Chlorhexidine (5 RCTs).
The ARR ranged from 2.8 to 25% and the NNT from 4 to 36 treated individuals.  Two high-quality RCTs showed statistically significant differences after 7 days in favour of the 0.12% chlorhexidine rinse compared with placebo (ARRs 11.2% and 25%; NNTs 8.9 and 4 , respectively).  However, 3 poor-quality RCTs of 0.2% chlorhexidine rinse in comparison with no treatment (2 RCTs) or saline rinse (1 RCT) failed to show any significant difference between the intervention and control groups.

PEPH trials (3 RCTs).
The ARR ranged from 6 to 26% and the NNT from 4.2 to 16.7 treated individuals.  Two high-quality RCTs showed significant differences in favour of PEPH in comparison with placebo (ARRs 26% and 24%; NNTs 3.8 and 4.2, respectively), but the largest high-quality RCT failed to show a statistically significant difference between the treatment and control groups.  All 3 trials were conducted by the same research group.

Other trials (18 RCTs).
Two poor-quality RCTs showed significant effects in favour of chlorhexidine, amoxicillin and clavulanic acid (ARR 14.8%, NNT 6.8) and chloraseptic (ARR 3.1% and NNT 32.3), in comparison with saline rinse and no treatment, respectively.  In 2 further high-quality RCTs diflunisal (ARR -29.7% and NNT -3.4) and polylactic acid (ARR -10% and NNT -10) granules were shown to have significantly worse effects than no treatment. The remaining trials failed to show any significant differences between the treatment and control groups.

Local tetracycline treatment and 0.12% chlorhexidine mouth rinse showed significant and clinically relevant preventive effects on AO following the surgical removal of lower third molars.

This review answered a clear research question that included a broad range of interventions and study populations.  The literature search did not appear to make specific attempts to locate unpublished material and, given that no assessment of publication bias was reported, such bias cannot be ruled out. There may also be a risk of language bias since restrictions were placed on the study languages included.  In general, the review methods attempted to reduce the risk of reviewer error and bias, although it is unclear how the studies were assessed for inclusion.  Study quality was assessed and considered in the analysis, as were differences between the studies.  The analysis focused only on the incidence of AO; the possible adverse effects of the interventions were not considered.  Given that the authors highlighted a number of potential serious adverse effects from tetracycline, the clinical implications of their findings should be interpreted with caution.  Overall, the authors’ conclusions appear to be supported by the data presented, but the paucity of studies assessing tetracycline and chlorhexidine, the small sample sizes and the poor quality of some of the studies, limits the reliability of these conclusions.

Practice: The authors did not state any implications for practice.

Research: The authors stated that further research in the form of high-quality, preferably double-blinded, RCTs with a priori power calculations are required to assess clinically relevant treatment effects and possible adverse effects of the interventions.  In particular, the authors highlighted the requirement for further trials of PEPH from other independent research groups and for trials of ‘other’ interventions that show clinically relevant or significant preventive effects.

Not stated.

This record is a structured abstract written by CRD reviewers. The original has met a set of quality criteria. Since September 1996 abstracts have been sent to authors for comment. Additional factual information is incorporated into the record. Noted as  [A:....].